Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets

  1. Kelsie M Rodriguez
  2. Sara C Buch-Larsen
  3. Ilsa T Kirby
  4. Ivan Siordia
  5. David Hutin
  6. Marit Rasmussen
  7. Denis M Grant
  8. Larry L David
  9. Jason Matthews
  10. Michael Lund Nielsen
  11. Michael S Cohen  Is a corresponding author
  1. Oregon Health and Science University, United States
  2. University of Copenhagen, Denmark
  3. University of California, San Francisco, United States
  4. University of Toronto, Canada
  5. University of Oslo, Norway

Abstract

Poly(ADP-ribose) polymerase 7 (PARP-7) has emerged as a critically important member of a large enzyme family that catalyzes ADP-ribosylation in mammalian cells. PARP-7 is a critical regulator of the innate immune response. What remains unclear is the mechanism by which PARP-7 regulates this process, namely because the protein targets of PARP-7 mono-ADP-ribosylation (MARylation) are largely unknown. Here, we combine chemical genetics, proximity labeling, and proteome-wide amino acid ADP-ribosylation site profiling for identifying the direct targets and sites of PARP-7-mediated MARylation in a cellular context. We found that the inactive PARP family member, PARP-13—a critical regulator of the antiviral innate immune response—is a major target of PARP-7. PARP-13 is preferentially MARylated on cysteine residues in its RNA binding zinc finger domain. Proteome-wide ADP-ribosylation analysis reveals cysteine as a major MARylation acceptor of PARP-7. This study provides insight into PARP-7 targeting and MARylation site preference.

Data availability

All RAW proteomics files have been uploaded to PRIDE. This is related to all Supplementary Tables.

The following data sets were generated

Article and author information

Author details

  1. Kelsie M Rodriguez

    Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Sara C Buch-Larsen

    Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6250-5467
  3. Ilsa T Kirby

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ivan Siordia

    Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. David Hutin

    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Marit Rasmussen

    Department of Nutrition, University of Oslo, Oslo, Norway
    Competing interests
    The authors declare that no competing interests exist.
  7. Denis M Grant

    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Larry L David

    Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jason Matthews

    Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
    Competing interests
    The authors declare that no competing interests exist.
  10. Michael Lund Nielsen

    The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  11. Michael S Cohen

    Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, United States
    For correspondence
    cohenmic@ohsu.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7636-4156

Funding

National Institute of Neurological Disorders and Stroke (NIH 2R01NS088629)

  • Michael S Cohen

Pew Charitable Trusts (NA)

  • Michael S Cohen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Rodriguez et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,098
    views
  • 680
    downloads
  • 61
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kelsie M Rodriguez
  2. Sara C Buch-Larsen
  3. Ilsa T Kirby
  4. Ivan Siordia
  5. David Hutin
  6. Marit Rasmussen
  7. Denis M Grant
  8. Larry L David
  9. Jason Matthews
  10. Michael Lund Nielsen
  11. Michael S Cohen
(2021)
Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-relevant protein targets
eLife 10:e60480.
https://doi.org/10.7554/eLife.60480

Share this article

https://doi.org/10.7554/eLife.60480

Further reading

    1. Biochemistry and Chemical Biology
    Adrian CD Fuchs
    Research Article

    The protein ligase Connectase can be used to fuse proteins to small molecules, solid carriers, or other proteins. Compared to other protein ligases, it offers greater substrate specificity, higher catalytic efficiency, and catalyzes no side reactions. However, its reaction is reversible, resulting in only 50% fusion product from two equally abundant educts. Here, we present a simple method to reliably obtain 100% fusion product in 1:1 conjugation reactions. This method is efficient for protein-protein or protein-peptide fusions at the N- or C-termini. It enables the generation of defined and completely labeled antibody conjugates with one fusion partner on each chain. The reaction requires short incubation times with small amounts of enzyme and is effective even at low substrate concentrations and at low temperatures. With these characteristics, it presents a valuable new tool for bioengineering.

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.